| Identification | Back Directory | [Name]
GYKI 11679 | [CAS]
69579-13-1 | [Synonyms]
RGH-5526
GYKI 11679
3-[2-[6-(4-Morpholinyl)-3-pyridazinyl]hydrazono]butanoic acid 1,1-dimethylethyl ester
Butanoic acid, 3-[2-[6-(4-morpholinyl)-3-pyridazinyl]hydrazinylidene]-, 1,1-dimethylethyl ester | [Molecular Formula]
C16H25N5O3 | [MDL Number]
MFCD01656131 | [MOL File]
69579-13-1.mol | [Molecular Weight]
335.4 |
| Chemical Properties | Back Directory | [Boiling point ]
472.04°C (rough estimate) | [density ]
1.0974 (rough estimate) | [refractive index ]
1.7500 (estimate) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO |
| Hazard Information | Back Directory | [Uses]
RGH-5526 (GYKI-11679) is a new antihypertensive agent. | [in vivo]
RGH-5526 (GYKI-11679) is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of RGH-5526, and this effect lasts for 4 to 6 h. It is demonstrated that RGH-5526 exerts a greater NA lowering effect in the hypothalamus than in the periphery. RGH-5526 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1]. | [storage]
Store at -20°C | [References]
[1] Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81. DOI:10.1111/j.1471-4159.1981.tb04678.x |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|